Overview A Study of PER-001 in Participants With Diabetic Retinopathy Status: Recruiting Trial end date: 2026-05-31 Target enrollment: Participant gender: Summary This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study. Phase: Phase 2 Details Lead Sponsor: Perfuse Therapeutics, Inc.